119-HR-7189 Journalist Public Summary

Headline Summary

A bill to let Medicare pay pharmacists for HIV prevention services—such as counseling, screening, and help with PrEP/PEP—beginning January 1, 2027.

What It Does

H.R. 7189, the “PrEP Access Act,” amends Medicare law so pharmacists can be paid under Part B for certain HIV‑prevention services they are allowed to provide under state law.

• Covers pharmacist-delivered prevention services: evaluation, management, screening, consultation, and counseling tied to pre‑exposure prophylaxis (PrEP), post‑exposure prophylaxis (PEP), and other evidence‑based HIV‑prevention measures.
• Includes related medication administration and certain clinical lab tests connected to those prevention services.
• Sets payment so Medicare pays 80% of the lesser of: the actual charge or 85% of the physician fee schedule amount for comparable services (standard Part B cost‑sharing would apply).
• Prohibits balance billing for these pharmacist services (patients cannot be charged above the Medicare‑approved amount).
• Effective for items and services furnished on or after January 1, 2027.

Why It Matters

• Access: Many people see a pharmacist more often than a doctor; allowing Medicare to pay pharmacists could make prevention advice, testing coordination, and PrEP/PEP starts easier to get—especially in rural or underserved areas.
• Speed: Post‑exposure prophylaxis works best when started quickly; pharmacist access may shorten delays.
• Continuity: Pharmacists can help with adherence, side‑effect checks, and refills—core to making PrEP effective.
• Medicare population: Applies to older adults and people with disabilities on Medicare, groups who can face transportation, scheduling, or provider‑availability barriers.

Who’s For It

• Introduced by Rep. Mark Pocan (D‑WI) on January 21, 2026, with Democratic co‑sponsors including Reps. Joyce Beatty, Madeleine Dean, Jesús “Chuy” García, Sylvia Garcia, Josh Gottheimer, Eleanor Holmes Norton, Hank Johnson, Delia Ramirez, Deborah Ross, Ritchie Torres, and Bonnie Watson Coleman.
• Supporters are likely to argue it reduces barriers to proven HIV‑prevention tools by meeting people where they already get care—at pharmacies—and by recognizing pharmacists’ role within state scope‑of‑practice rules.

Who’s Against It

• As of introduction (January 21, 2026), no formal opposition is recorded in the bill text or actions. Public positions may emerge as the bill moves through committees.
• Potential concerns typically raised in similar debates: costs to Medicare, overlap with physician services, varying state laws on pharmacist authority, and questions about reimbursement levels and quality oversight for lab ordering and follow‑up.

What’s Next

• Status: Introduced in the House on January 21, 2026 and referred to the Energy & Commerce Committee and the Ways & Means Committee the same day.
• Process: Committees may hold hearings and markups. If reported, the bill goes to the full House for a vote, then to the Senate. If both chambers pass identical text, it goes to the President.
• Timing note: If enacted, coverage would begin for services furnished on or after January 1, 2027.